Compound News and Research

RSS

Levi Strauss, Hennes & Mauritz implement global ban on sandblasting

As a commitment to the health and safety of workers across the apparel industry, Levi Strauss & Co. and Hennes & Mauritz AB (H&M) today announced plans to implement a global ban on sandblasting in all of their future product lines.

8 Sep 2010

Researchers find blebbistatin chemically inhibits NMII, enhances survival of stem cells

Human pluripotent stem (hPS) cells can generate any given cell type in the adult human body, which is why they are of interest to stem cell scientists working on finding therapies for spinal cord injuries, Parkinson's disease, burns, heart disease, diabetes, arthritis, and other ailments.

8 Sep 2010

NGP 555 compound effective in preventing amyloid pathology of Alzheimer's disease

In the Sept. 9, 2010 issue of Neuron, Neurogenetic Pharmaceuticals, Inc. (NGP) reports proof of concept studies that show its proprietary compound, NGP 555, is effective in preventing the amyloid pathology of Alzheimer's disease (AD) in a transgenic mouse model.

8 Sep 2010

Biomoda joins Saccomanno Research Institute to advance CyPath technology for cancer detection

Cancer diagnostics company Biomoda, Inc. is working with the Saccomanno Research Institute to advance Biomoda's patented system for measuring the photon emission rate of CyPath-stained cells to detect early-stage lung cancer.

8 Sep 2010

Positive immune responses elicited from Scancell's DNA vaccine in combination with ImmuneRegen's Homspera

Scancell Holdings Plc, the developer of therapeutic cancer vaccines, announces that a treatment utilising a DNA vaccine based on its ImmunoBody® technology, in combination with ImmuneRegen BioSciences, Inc.®'s lead compound, Homspera®, has significantly improved the immune response of the vaccine in an animal model. Follow-up studies are currently being performed to optimize the effects of Homspera in enhancing the next generation of Scancell's cancer vaccines.

7 Sep 2010

Bend Research expands hot-melt extrusion pharmaceutical manufacturing capabilities

Bend Research Inc., a leading independent drug-formulation development and manufacturing company, announced today that it is expanding its pharmaceutical manufacturing capabilities for hot-melt extrusion.

7 Sep 2010

TenX Biopharma recommences enrollment in suspended Phase III trial for cutaneous T-cell lymphoma

TenX Biopharma, Inc. announced today that it has re-initiated enrollment in the pivotal Phase III clinical trial assessing zanolimumab treatment for cutaneous T-cell lymphoma (CTCL) patients (ClinicalTrials.gov identifier: NCT00127881). The trial enrollment was suspended in October 2008 while Genmab was seeking a out-license agreement to further develop the compound. TenX Biopharma acquired global rights to zanolimumab in February, 2010 from Genmab.

7 Sep 2010

DSM, PolyTherics enter agreement for HiPEG IFN alpha-2a product development

DSM BioSolutions, DSM's microbial fermentation CMO business unit and PolyTherics Limited an innovator in precision engineering of proteins, today announced that they have entered into an agreement for the process development and manufacture of PolyTherics' lead biobetter product, HiPEG IFN alpha-2a.

7 Sep 2010

Chemicals in non-stick cookware elevates cholesterol level among children: Report

Children and teens with higher blood levels of chemicals used in the production of non-stick cookware and waterproof fabrics appear more likely to have elevated total and LDL cholesterol levels, according to a report in the September issue of Archives of Pediatrics & Adolescent Medicine, one of the JAMA/Archives journals.

7 Sep 2010

Single-dose of experimental malaria drug clears parasites in mice, represents potential new class of drugs to treat malaria in humans

An experimental malaria drug was shown to effectively treat the disease in mice with only a single dose, according to a study published Thursday in the journal Science, Reuters reports (Kelland, 9/2). The new drug, known as NITD609, "represents an entirely new class of medicines to treat malaria ... Human trials, backed by Swiss pharmaceutical giant Novartis AG, could begin later this year," the Wall Street Journal writes (Naik, 9/3).

4 Sep 2010

MIT develops safer, simpler way to attach phosphorus to organic compounds

Phosphorus, a mineral element found in rocks and bone, is a critical ingredient in fertilizers, pesticides, detergents and other industrial and household chemicals. Once phosphorus is mined from rocks, getting it into these products is hazardous and expensive, and chemists have been trying to streamline the process for decades.

4 Sep 2010

Researchers reveal new details on bacterial cannibalism

Researchers at the University of California, San Diego have revealed new details about how cannibalistic bacteria identify peers suitable for consumption. The work, which employed imaging mass spectrometry, is a first step toward a broader effort to map all signaling molecules between organisms.

4 Sep 2010

Researchers complete INX-189 clinical trials for Hepatitis C virus

The first clinical trials on a new investigational drug being developed to treat infections caused by Hepatitis C virus have been successfully completed.

3 Sep 2010

Study shows molecular imaging benefits treatment planning for wide spectrum of cancers

A series of studies published in the September Journal of Nuclear Medicine (JNM) show that molecular imaging plays a critical role in the evaluation and treatment planning for a broad spectrum of cancers, including thyroid cancer and lymphoma.

3 Sep 2010

Santhera, Ipsen partner to develop and commercialize fipamezole outside North America and Japan

Santhera Pharmaceuticals and Ipsen today announced a license agreement for the development and commercialization of fipamezole (antagonist of the adrenergic alpha-2 receptor) for territories outside of North America and Japan. This first-in-class compound is currently under investigation for the treatment of levodopa-induced dyskinesia in Parkinson's Disease.

3 Sep 2010

Capsaicin linked to skin cancer

The September cover story of the nation's leading cancer journal, "Cancer Research," features a new study from The Hormel Institute, University of Minnesota, that links capsaicin, a component of chili peppers, to skin cancer. While the molecular mechanisms of the cancer-promoting effects of capsaicin are not clear and remain controversial, The Hormel Institute has shown a definite connection to formation of skin cancer through various laboratory studies.

3 Sep 2010

Diabetes drug metformin exhibits potential against tobacco-induced lung tumors

Metformin, a drug commonly used to treat type 2 diabetes, shows potential in the prevention of tobacco-induced lung tumors, according to early research conducted at the National Cancer Institute (NCI).

3 Sep 2010

Rexahn Pharmaceuticals publishes research article on RX-8243 anti-tumor activity

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced the publication of a research article in Bioorganic & Medicinal Chemistry Letters on the anti-tumor activity of RX-8243 and its analogues.

3 Sep 2010

Researchers discover novel compound to combat drug resistant malaria

Novartis announced today that scientists at the Novartis Institute for Tropical Diseases (NITD), in collaboration with researchers from the Genomics Institute of the Novartis Research Foundation (GNF), the Swiss Tropical and Public Health Institute and The Scripps Research Institute have discovered a novel compound that shows promise as a next generation treatment for drug resistant malaria.

3 Sep 2010

Emergent BioSolutions signs contract with NIAID to develop third generation anthrax vaccine candidate

Emergent BioSolutions Inc. announced today that it has signed a contract valued at up to $28.7 million with the National Institute of Allergy and Infectious Diseases, an institute within the National Institutes of Health, for advanced development of the company's third generation anthrax vaccine candidate.

2 Sep 2010

Compound News and Research

Levi Strauss, Hennes & Mauritz implement global ban on sandblasting

Researchers find blebbistatin chemically inhibits NMII, enhances survival of stem cells

NGP 555 compound effective in preventing amyloid pathology of Alzheimer's disease

Biomoda joins Saccomanno Research Institute to advance CyPath technology for cancer detection

Positive immune responses elicited from Scancell's DNA vaccine in combination with ImmuneRegen's Homspera

Bend Research expands hot-melt extrusion pharmaceutical manufacturing capabilities

TenX Biopharma recommences enrollment in suspended Phase III trial for cutaneous T-cell lymphoma

DSM, PolyTherics enter agreement for HiPEG IFN alpha-2a product development

Chemicals in non-stick cookware elevates cholesterol level among children: Report

Single-dose of experimental malaria drug clears parasites in mice, represents potential new class of drugs to treat malaria in humans

MIT develops safer, simpler way to attach phosphorus to organic compounds

Researchers reveal new details on bacterial cannibalism

Researchers complete INX-189 clinical trials for Hepatitis C virus

Study shows molecular imaging benefits treatment planning for wide spectrum of cancers

Santhera, Ipsen partner to develop and commercialize fipamezole outside North America and Japan

Capsaicin linked to skin cancer

Diabetes drug metformin exhibits potential against tobacco-induced lung tumors

Rexahn Pharmaceuticals publishes research article on RX-8243 anti-tumor activity

Researchers discover novel compound to combat drug resistant malaria

Emergent BioSolutions signs contract with NIAID to develop third generation anthrax vaccine candidate

Advancing therapeutic biopolymer development eBook

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News